Caribou Biosciences

CRBU

----

Current ValuationThe current P/E ratio is -0.49, above the reasonable range, cheaper than 1.53% of the time in the past 3 years, and the industry ranks 150/604, the industry Median -2.00.

-0.487xP/E

Stock price$0.47Earnings per share$-0.96

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

020406080

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
GILDUSGilead Sciences	-56.61x	150.48%	$183.41B
MRNAUSModerna	-27.40x	15.53%	$86.33B
CSLLYUSCSL Limited	-23.90x	--	$61.63B
NTRAUSNatera	-296.50x	7.27%	$57.03B
RVMDUSRevolution Medicines	-22.84x	62.12%	$40.39B
ROIVUSRoivant Sciences	-90.48x	146.49%	$24.09B
BNTXUSBioNTech SE	-11.44x	19.07%	$22.36B
INSMUSInsmed	-24.15x	74.49%	$21.14B
SMMTUSSummit Therapeutics	-14.46x	20.52%	$12.38B
BBIOUSBridgebio Pharma	-17.89x	28.98%	$12.37B
PCVXUSVaxcyte	-9.88x	48.18%	$10.51B
MDGLUSMadrigal Pharma	-32.13x	51.27%	$10.45B
IBRXUSImmunityBio	-10.47x	151.32%	$10.39B
TWSTUSTwist Bioscience	-72.87x	28.71%	$9.96B
KYMRUSKymera Therapeutics	-29.61x	5.24%	$8.87B
CYTKUSCytokinetics	-9.58x	6.46%	$8.57B
ARWRUSArrowHead Pharma	-25.66x	36,308.30%	$8.21B
ABVXUSAbivax SA	-16.16x	22.49%	$7.52B
SYREUSSpyre Therapeutics	-47.22x	45.67%	$7.09B
IONSUSIonis Pharma	-12.46x	50.60%	$7.04B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.